{"organizations": [], "uuid": "da932ce098e91b95dc4808fa268ed85aa7ae70a0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/13/globe-newswire-avivagen-announces-the-issuance-of-stock-options.html", "country": "US", "domain_rank": 767, "title": "Avivagen Announces the Issuance of Stock Options", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.014, "site_type": "news", "published": "2018-04-14T00:15:00.000+03:00", "replies_count": 0, "uuid": "da932ce098e91b95dc4808fa268ed85aa7ae70a0"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/13/globe-newswire-avivagen-announces-the-issuance-of-stock-options.html", "ord_in_thread": 0, "title": "Avivagen Announces the Issuance of Stock Options", "locations": [], "entities": {"persons": [], "locations": [{"name": "ottawa", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "charlottetown", "sentiment": "none"}, {"name": "prince edward island", "sentiment": "none"}, {"name": "ottawa", "sentiment": "none"}], "organizations": [{"name": "avivagen inc.", "sentiment": "negative"}, {"name": "avivagen", "sentiment": "none"}, {"name": "avivagen avivagen inc.", "sentiment": "none"}, {"name": "national research council of canada", "sentiment": "none"}, {"name": "tsx venture exchange", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "OTTAWA, Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces that its Board of Directors has approved the issuance of 652,541 stock options, including option grants to directors and officers. These stock options were granted pursuant to the terms of Avivagen’s stock option plan and are exercisable at $0.90 per share. The options form part of the total remuneration package for the recipients. Stock option grants are subject to TSX Venture Exchange approval.\nABOUT AVIVAGEN\nAvivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com .\nAbout OxC-beta™ Technology and OxC-beta™ Livestock\nAvivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.\nAvivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.\nAbout Vivamune™ Health Chews (Vivamune)\nVivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit www.vivamunehealth.com .\nForward Looking Statements\nThis news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates that could cause actual results or events to differ materially from current expectations. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. For example, statements regarding the potential for OxC-beta™ Livestock to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nFor more information:\nAvivagen Inc.\nDrew Basek\nDirector of Investor Relations\n100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6\nPhone: 416-540-0733\nE-mail: d.basek@avivagen.com\nKym Anthony\nChairman & Interim CEO\n100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6\nHead Office Phone: 613-949-8164\nWebsite: www.avivagen.com\nCopyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.\nSource: Avivagen Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=b6poh0GgqLQfQ-5o_KgNFghW4Aih0WyKelpEhnNcm2rSQdYUl4TAAg78zZXN4gpf5bq9C6oriMePj5jEgWmo6w==", "https://www.globenewswire.com/Tracker?data=TPqfhSH7OE06M4Pv-fmGd3jaRMPnkNBUKettgtKGSgC8Nma8bGN-Ui4yskk9KDm0H6ANdykYNwd0FKeYV_fXd6k-HkX8NMzvnFs_SISHXGM=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/36d34616-cf91-499e-8119-1b4c5fbee0ab", "https://www.globenewswire.com/Tracker?data=6IMdPEtfdD-hLLCyK-Qy5AS01JoknbGkWZ_-82DaHYuNb5ywl37m0gvmvlEOj3eqzfCmiArGoSLXeALHvewe0Hr08oRAbsctZfeVaEi_eYQ=", "https://www.globenewswire.com/Tracker?data=b6poh0GgqLQfQ-5o_KgNFlI-JGisxhX0v2GXogaYBGs5JqI4EifRmmI_3Qg0hkb3k28ySEa2vJmHhpq70T2DxA=="], "published": "2018-04-14T00:15:00.000+03:00", "crawled": "2018-04-14T00:24:51.000+03:00", "highlightTitle": ""}